Spinal sarcomas and immunity: An undervalued relationship

Semin Cancer Biol. 2020 Aug:64:36-50. doi: 10.1016/j.semcancer.2019.06.009. Epub 2019 Jun 26.

Abstract

Sarcomas, especially spine sarcomas, are rare yet debilitating and are underestimated types of cancer. Treatment options for spine sarcomas are limited to chemotherapy, radiotherapy and surgical intervention. Accumulating evidence suggests a complex course associated with the treatment of spine sarcomas as compared to other soft tissue sarcomas in the extremities since adjuvant therapy adds limited success to the oncological outcome. Likewise, the limitations of surgical interventions imposed by the proximity and high sensitivity of the spinal cord, leads to an increased recurrence and mortality rates associated with spine sarcomas. Finding novel treatment options to spine sarcomas as such is inevitable, necessitating a more thorough understanding of the different mechanisms of the underlying etiologies of these tumors. In this review, we discuss the most recent studies tackling the involvement of the immune system; a key player in the emergence of the different types of spine sarcomas and the promising immune-mediated targeted therapy that can be applied in these kind of rare cancers.

Keywords: Chemotherapy; Chondrosarcoma; Ewing sarcoma; Immune therapy; Osteosarcoma; Radiotherapy; Spine sarcoma.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents, Immunological / therapeutic use*
  • Humans
  • Immune System / immunology*
  • Sarcoma / drug therapy
  • Sarcoma / immunology
  • Sarcoma / pathology*
  • Spinal Neoplasms / drug therapy
  • Spinal Neoplasms / immunology
  • Spinal Neoplasms / pathology*

Substances

  • Antineoplastic Agents, Immunological